REPL — Replimune Group, Inc. Stock Price, Chart & AI Report

Positive Jan 23, 2026 • 10:52 UTC GlobeNewswire Inc. • Researchandmarkets.Com

Oncolytic Virotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The global oncolytic virotherapy market is projected to grow from USD 49.73 million in 2025 to USD 153.31 million by 2031, with a CAGR of 20.64%. Growth is driven by rising cancer incidence, advances in genetic engineering, and synergistic combination therapies with checkpoint inhibitors. However, host immune system challenges and premature viral clearance remain significant obstacles to market expansion.

NVS PFE GSK REPL oncolytic virotherapy cancer treatment genetic engineering checkpoint inhibitors

Sentiment note

Demonstrated strong clinical results with RP1 and nivolumab combination showing 75.3% 1-year overall survival rate in anti-PD1 failed melanoma patients, validating commercial and therapeutic potential.

Positive Nov 7, 2025 • 21:45 UTC GlobeNewswire Inc. • Replimune Group, Inc.

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Replimune presented biomarker data showing RP1 plus nivolumab can potentially reverse resistance mechanisms to PD-1 blockade in advanced melanoma, demonstrating a 33.6% response rate and 24.8-month median response duration.

REPL immunotherapy melanoma oncolytic clinical trial PD-1 blockade

Sentiment note

Presented promising clinical trial results showing potential breakthrough in melanoma treatment, with positive data on reversing resistance mechanisms

Positive Oct 20, 2025 • 20:10 UTC The Motley Fool • Eric Volkman

Why Replimune Stock Was Soaring Today

Replimune Group's stock surged after the FDA accepted its resubmitted Biologics License Application for RP1, an investigational drug targeting advanced melanoma when combined with Bristol Myers Squibb's Opdivo.

REPL BMY CELGR biotech FDA melanoma drug application cancer treatment

Sentiment note

Stock more than doubled after FDA accepted its drug application, resolving previous regulatory concerns

Positive Oct 20, 2025 • 11:00 UTC GlobeNewswire Inc. • Sushil Patel, Ph.D., Ceo Of Replimune

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Replimune Group resubmitted a Biologics License Application to the FDA for RP1, an oncolytic immunotherapy for advanced melanoma patients who progressed on anti-PD-1 therapy. The PDUFA date is set for April 10, 2026.

REPL oncolytic immunotherapy melanoma FDA BLA nivolumab

Sentiment note

Company is progressing with FDA review of its lead product candidate, addressing previous feedback and moving closer to potential drug approval

Positive Oct 19, 2025 • 12:00 UTC GlobeNewswire Inc. • Replimune Group, Inc.

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

Replimune reported positive phase 2 clinical trial results for RP1, an oncolytic immunotherapy, when combined with nivolumab in treating acral melanoma. The treatment showed a 44% objective response rate and a favorable safety profile for patients who had progressed on previous therapies.

REPL BMY CELGR immunotherapy melanoma oncolytic clinical trial cancer treatment

Sentiment note

Demonstrated promising clinical trial results with statistically significant response rates in a challenging cancer type, indicating potential therapeutic advancement

Negative Sep 21, 2025 • 15:20 UTC GlobeNewswire Inc. • Hagens Berman

REPL FINAL DEADLINE ALERT: Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman

Replimune's stock plummeted 45% after the FDA rejected its Biologics License Application for RP1, a cancer drug, citing inadequate trial design. A securities class action lawsuit alleges the company misled investors about the drug's prospects.

REPL FDA BLA securities lawsuit drug approval clinical trial

Sentiment note

Stock dropped 77% after FDA rejection, facing a securities lawsuit alleging misleading investors about drug trial results and approval likelihood

Negative Sep 21, 2025 • 11:40 UTC GlobeNewswire Inc. • James (Josh) Wilson

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Faruqi & Faruqi, LLP is investigating potential securities claims against Replimune Group after the FDA issued a Complete Response Letter for their RP1 Biologics License Application, causing the stock to drop over 73%.

REPL securities litigation FDA Biologics License Application class action lawsuit

Sentiment note

Received a Complete Response Letter from FDA rejecting their Biologics License Application for RP1, indicating the IGNYTE trial was not considered adequate, which caused a 73% stock price drop

Negative Sep 21, 2025 • 10:09 UTC GlobeNewswire Inc. • Rosen Law Firm

REPL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL

Rosen Law Firm reminds Replimune Group investors of an important September 22, 2025 deadline for a securities class action lawsuit, alleging the company made false or misleading statements about its IGNYTE trial prospects.

REPL securities lawsuit class action FDA investor rights

Sentiment note

The lawsuit alleges the company made materially false and misleading statements about its IGNYTE trial, which the FDA deemed inadequate, suggesting potential misconduct and potential financial harm to investors

Negative Sep 21, 2025 • 10:09 UTC GlobeNewswire Inc. • Rosen Law Firm

מחר המועד האחרון לתביעה נגד REPL: רוזן, יועץ למשקיעים מיומן, מעודד את משקיעי Replimune Group, Inc. שצברו הפסדים של יותר מ- 100 אלף דולר להבטיח ייעוץ לפני המועד האחרון החשוב בתביעה ייצוגית בניירות ערך שהוגשה ראשונה על ידי המשרד – REPL

Rosen Law Firm alerts investors of Replimune Group and RxSight who suffered losses over $100,000 about an upcoming September 22, 2025 deadline for filing securities class action lawsuits related to allegedly misleading statements.

REPL RXST securities lawsuit investor rights class action financial disclosure

Sentiment note

Lawsuit alleges company made false or misleading statements about legal prospects and business performance, potentially causing investor financial harm

Negative Sep 17, 2025 • 22:00 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. and Encourages Investors to Contact the Firm Before September 22nd

A class action lawsuit has been filed against Replimune Group, Inc. alleging false statements about the IGNYTE trial's prospects, which the FDA deemed inadequate and not well-controlled.

REPL class action lawsuit securities FDA trial

Sentiment note

The lawsuit claims the company made misleading statements about its clinical trial, resulting in potential investor damages and FDA rejection of the trial's methodology

Negative Sep 17, 2025 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against Replimune Group alleging false and misleading statements about the IGNYTE trial's prospects, which the FDA deemed inadequate and not well-controlled.

REPL class action securities lawsuit FDA trial investor alert

Sentiment note

Lawsuit alleges company made materially false statements about clinical trial prospects, potentially misleading investors about the company's business operations and future potential

Negative Sep 16, 2025 • 20:53 UTC GlobeNewswire Inc. • Portnoy Law Firm

Replimune Group, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 22, 2025 Deadline to file Lead Plaintiff Motion.

Replimune Group faces a class action lawsuit alleging misleading statements about its IGNYTE trial for cancer immunotherapy. The FDA issued a Complete Response Letter rejecting the Biologics License Application for RP1, causing the stock to drop over 77%.

REPL class action biotechnology FDA immunotherapy stock decline

Sentiment note

The company received a Complete Response Letter from the FDA, indicating significant issues with their clinical trial data, which led to a substantial stock price drop of over 77% and potential legal action by investors